Skip to main content

ScienceDex / Researcher record

Moore, Anna

From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.

FY2023 NIH rank #15,082
  • R01 Holder
  • Long-Funded
  • Translational

NIH Funding · FY2023

$737.9K
Full award amounts, FY2023
2
Records listing this PI
#15,082
By linked amount among FY2023 PIs
2006
ScienceDex PI coverage

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

Linked awards ($M)Award-linked rank
View yearly values
Award-linked funding and rank by fiscal year
Fiscal yearLinked awardsRecordsRank
2006$1,194,8044#4,137
2007$1,650,1684#3,512
2008$1,225,0673#4,794
2009$1,584,0924#4,512
2010$1,223,1444#6,468
2011$1,110,4793#6,181
2012$189,2831#32,671
2013$909,0092#7,293
2014$670,3231#11,216
2015$1,116,2372#5,995
2016$1,116,2372#6,047
2017$1,080,3314#6,295
2018$1,013,4972#7,405
2019$1,013,4972#7,986
2021$7,869,7443#355
2022$1,347,2003#6,623
2023$737,9402#15,082

Award activity

Awards through the years

NIH award records listing this researcher in each fiscal year.

  1. FY20064 records
  2. FY20074 records
  3. FY20083 records
  4. FY20094 records
  5. FY20104 records
  6. FY20113 records
  7. FY20121 record
  8. FY20132 records
  9. FY20141 record
  10. FY20152 records
  11. FY20162 records
  12. FY20174 records
  13. FY20182 records
  14. FY20192 records
  15. FY20213 records
  16. FY20223 records
  17. FY2023 · selected2 records

Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Moore, Anna. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2023 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets About this stat →

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Publications

Loading publications…

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID unavailableSearch this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2006 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.

FY2023 award categories

  • Physiology
  • Radiology

FY2023 award records by amount

NIH award records listing Moore, Anna as a PI. Multi-PI records show the full award amount for context.

  • 5R01CA261691-03R01Contact PI
    anti-miR-10b Nanodrug for Treatment of Breast Cancer Metastasis: Study in Companion Animals
    Michigan State University · Physiology (NIH department code)
    $556.9K
    award amount
  • 5R21CA245343-02R21Contact PI
    Novel Prostate cancer therapy based on m-aconitase inhibition
    Michigan State University · Radiology (NIH department code)
    $181.1K
    award amount

Award organization

Organizations that administered FY2023 awards listing Moore, Anna as a PI.

FY2023 award administered by Michigan State University (MI).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2006
    First NIH Award
    Michigan State University
  2. 2006
    $500K Cumulative Funding
  3. 2006
    $1M Cumulative Funding
  4. 2006
    Entered Top 50% Nationally
    Ranked #4137
  5. 2006
    Entered Top 25% Nationally
    Ranked #4137
  6. 2007
    $2M Cumulative Funding
  7. 2009
    $5M Cumulative Funding
  8. 2011
    R01 Grant Holder
  9. 2015
    $10M Cumulative Funding
  10. 2021
    Entered Top 10% Nationally
    Ranked #355
  11. 2021
    Entered Top 5% Nationally
    Ranked #355
  12. 2023
    $25M Cumulative Funding